DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Xolair (Omalizumab) - Published Studies

 


Nutrilib.com
A comprihensive source of nutritional information

Xolair Related Published Studies

Well-designed clinical trials related to Xolair (Omalizumab)

Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. [2008.05]

Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. [2008.02]

Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. [2008]

Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. [2007.10]

Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. [2007.09]

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. [2007.09]

Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. [2007.02]

[Omalizumab as a therapeutic option in atopic eczema : Current evidence and potential benefit.] [2007.02]

[Omalizumab as a therapeutic option in atopic eczema : Current evidence and potential benefit.] [2007.01.20]

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. [2006.06]

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. [2006.01]

Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma. [2006]

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. [2005.09]

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. [2005.03]

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. [2004.09.15]

Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. [2004.09]

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. [2004.08]

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. [2004.07]

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. [2004.07]

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. [2004.04]

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. [2004.04]

Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. [2004.04]

Omalizumab inhibits allergen challenge-induced nasal response. [2004.03]

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. [2004.02]

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. [2003.12]

Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab). [2003.10]

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. [2003.08]

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. [2003.08]

Omalizumab is effective in the long-term control of severe allergic asthma. [2003.08]

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. [2003.05]

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. [2003.02]

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. [2003.01]

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. [2002.11]

Omalizumab improves asthma-related quality of life in children with allergic asthma. [2002.11]

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. [2002.07]

The effect of omalizumab on nasal allergic inflammation. [2002.07]

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. [2001.12.19]

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. [2001.08]

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. [2001.08]

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). [2001.08]

Well-designed clinical trials possibly related to Xolair (Omalizumab)

Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. [2008.04]

The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. [2006.09]

The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. [2004.09]

Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. [2004.07]

The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. [2002.11]

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. [2002.02]

Other research related to Xolair (Omalizumab)

Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. [2008.10]

Treatment of chronic autoimmune urticaria with omalizumab. [2008.09]

Anti-IgE Antibody Therapy for Japanese Cedar Pollinosis: Omalizumab Update. [2008.09]

Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study. [2008.07.25]

Churg-Strauss syndrome associated with omalizumab. [2008.07]

An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. [2008.06]

Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. [2008.06]

The use of omalizumab in asthma. [2008.06]

Reduction of the total IgE level by omalizumab in children and adolescents. [2008.04]

Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis. [2008.04]

Churg-Strauss vasculitis in a patient treated with omalizumab. [2008.03]

Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. [2008.02]

[Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] [2008.01]

Omalizumab: a review of its use in the treatment of allergic asthma. [2008]

[Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine] [2007.12.10]

Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. [2007.12.07]

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. [2007.12]

[Application of humanized Anti-IgE antibodies (omalizumab). A new principle in the treatment of allergic diseases in ENT medicine] [2007.12]

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. [2007.12]

Use of omalizumab in a severe asthma clinic. [2007.11]

Omalizumab (Xolair) in patients with steroid-resistant asthma: lessons to be learnt. [2007.11]

Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. [2007.11]

CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. [2007.10]

Anti-immunoglobulin E therapy with omalizumab for asthma. [2007.09]

Effect of omalizumab on patients with chronic urticaria. [2007.08]

Predicting and evaluating response to omalizumab in patients with severe allergic asthma. [2007.07]

Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. [2007.07]

The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study. [2007.06]

The effects of repeat omalizumab administration on skin test positivity and the assessment of the safety of administration in patients with positive skin tests to mouse antigen. [2007.05]

Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. [2007.05]

The appropriate omalizumab patient. [2007.05]

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. [2007.05]

[Omalizumab (Xolair). Product description] [2007.03.12]

Predicting and evaluating response to omalizumab in patients with severe allergic asthma. [2007.03.03]

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. [2007.02]

Omalizumab decreases nonspecific airway hyperresponsiveness in vitro. [2007.02]

Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). [2007.01]

Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. [2006.12]

Improvement in quality of life with omalizumab in patients with severe allergic asthma. [2006.11]

Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. [2006.11]

Improvement of asthma control with omalizumab in 2 obese pediatric asthma patients. [2006.09]

Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. [2006.09]

[Omalizumab in severe asthma--case report] [2006.08]

The role of omalizumab in the treatment of severe allergic asthma. [2006.07]

[Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma] [2006.05]

Characterization of an anaphylactoid reaction to omalizumab. [2006.04]

Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). [2006.04]

Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. [2006.03.08]

Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. [2006.02]

Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. [2006.02]

Treatment of recalcitrant atopic dermatitis with omalizumab. [2006.01]

IgE, allergic diseases, and omalizumab. [2006]

[Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma] [2006]

Effect of Omalizumab on Adenosine 5'-Monophosphate Responsiveness in Subjects with Allergic Asthma. [2005.12.21]

Symptom Control and Improved Functioning: The Effect of Omalizumab on Asthma-Related Quality of Life (ARQL). [2005.12]

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008